The question everyone should be asking about Moberg is why would a company that's too conservative to guide to capturing a substantial portion of European OTC market risk everything on a trial with a different dosing regimen. Afterall they didnt need to go as far as 8 weeks, they knew the whitening fades after around 8 weeks given they missed it in the P2.
The answer is probably that elucidating a dosing regimen to the FDA is more useful than replicating an outcome. It won't get an improved label, but if this trial failed or the efficacy was lower due to a DDR, it just puts the label europe already has into the other markets.
Great post! Tough week for the Moberg bag holders like myself but this is my favorite writeup yet.
Have you written on what tools you use company discovery, tracking potential investments, etc? I'm looking for free or low cost tools and right now I'm just at a notion doc plus Schwab's tools.
Thanks. To be honest, I'm extremely bare bones. Don't you screeners or any paid tools. Mostly just following rabbits holes until they lead to something.
Another great post. CPH grew up to almost 40% of my portfolio at one point. I can see what you mean about balancing large holdings that you have high conviction in. Definitely a different experience as your portfolio grows in value.
It seems like so many on social media/X like to utilize the volatility to justify their way of over diversifying. They will over fixate on a day or week of volatility and not look back 6 months or a year. Pretty sad actually.
Thanks Dean. Agree - unless you're operating under short-term performance mandates/comp structures, or have a short-term need for cash (retirement age, dependents, etc.) then volatility shouldn't be an issue if you know what you own well enough.
The question everyone should be asking about Moberg is why would a company that's too conservative to guide to capturing a substantial portion of European OTC market risk everything on a trial with a different dosing regimen. Afterall they didnt need to go as far as 8 weeks, they knew the whitening fades after around 8 weeks given they missed it in the P2.
The answer is probably that elucidating a dosing regimen to the FDA is more useful than replicating an outcome. It won't get an improved label, but if this trial failed or the efficacy was lower due to a DDR, it just puts the label europe already has into the other markets.
Great post! Tough week for the Moberg bag holders like myself but this is my favorite writeup yet.
Have you written on what tools you use company discovery, tracking potential investments, etc? I'm looking for free or low cost tools and right now I'm just at a notion doc plus Schwab's tools.
Thanks. To be honest, I'm extremely bare bones. Don't you screeners or any paid tools. Mostly just following rabbits holes until they lead to something.
Another great post. CPH grew up to almost 40% of my portfolio at one point. I can see what you mean about balancing large holdings that you have high conviction in. Definitely a different experience as your portfolio grows in value.
It seems like so many on social media/X like to utilize the volatility to justify their way of over diversifying. They will over fixate on a day or week of volatility and not look back 6 months or a year. Pretty sad actually.
Keep up the good work.
Thanks Dean. Agree - unless you're operating under short-term performance mandates/comp structures, or have a short-term need for cash (retirement age, dependents, etc.) then volatility shouldn't be an issue if you know what you own well enough.
Great piece again. IMO it can all be broken down into the most important investing rules; 1) never loose money 2) dont forget 1)
Would probably have made for a less interesting read lol but that is indeed what it all comes down to.